News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
CyGenics Ltd Limited Expands With 20% Stake In PharmaCell BV Cell Therapy
June 5, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CyGenics Ltd. (ASX: CYN) today formally completed its strategic investment of an initial 20% stake in Dutch-based Pharmacell BV, with an option to purchase the remaining 80% at a later date.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Australia
MORE ON THIS TOPIC
Collaboration
Novartis Bets Up to $1.7B in Cardio-Focused Peptide Partnership
February 19, 2026
·
2 min read
·
Tristan Manalac
Collaboration
Lilly Fronts $100M for CSL’s IL-6 Blocker to Bolster I&I, Cardiovascular Pipeline
February 18, 2026
·
2 min read
·
Tristan Manalac
Venture capital
Early-Stage Biotechs Suffer in 2025 As VC Shuns Risk: PitchBook
February 18, 2026
·
2 min read
·
Annalee Armstrong
Rare diseases
BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work?
February 12, 2026
·
4 min read
·
Dan Samorodnitsky
